These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 27687306)

  • 1. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
    Kadara H; Choi M; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Yoo Y; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Wistuba II; Herbst RS
    Ann Oncol; 2017 Jan; 28(1):75-82. PubMed ID: 27687306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.
    Choi M; Kadara H; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Kim K; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Herbst RS; Wistuba II
    Ann Oncol; 2017 Jan; 28(1):83-89. PubMed ID: 28177435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma.
    Behrens C; Rocha P; Parra ER; Feng L; Rodriguez-Canales J; Solis LM; Mino B; Zhang J; Gibbons DL; Sepesi B; Rice D; Heymach JV; Moran C; Creighton CJ; Lee JJ; Kadara H; Wistuba II
    Clin Lung Cancer; 2021 May; 22(3):e415-e424. PubMed ID: 32763065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Kras mutant lung adenocarcinoma in mice with knockout of the airway lineage-specific gene Gprc5a.
    Fujimoto J; Nunomura-Nakamura S; Liu Y; Lang W; McDowell T; Jakubek Y; Ezzeddine D; Kapere Ochieng J; Petersen J; Davies G; Fukuoka J; Wistuba II; Ehli E; Fowler J; Scheet P; Kadara H
    Int J Cancer; 2017 Oct; 141(8):1589-1599. PubMed ID: 28653505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
    Ricciuti B; Arbour KC; Lin JJ; Vajdi A; Vokes N; Hong L; Zhang J; Tolstorukov MY; Li YY; Spurr LF; Cherniack AD; Recondo G; Lamberti G; Wang X; Venkatraman D; Alessi JV; Vaz VR; Rizvi H; Egger J; Plodkowski AJ; Khosrowjerdi S; Digumarthy S; Park H; Vaz N; Nishino M; Sholl LM; Barbie D; Altan M; Heymach JV; Skoulidis F; Gainor JF; Hellmann MD; Awad MM
    J Thorac Oncol; 2022 Mar; 17(3):399-410. PubMed ID: 34740862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma.
    Rocha P; Salazar R; Zhang J; Ledesma D; Solorzano JL; Mino B; Villalobos P; Dejima H; Douse DY; Diao L; Mitchell KG; Le X; Zhang J; Weissferdt A; Parra-Cuentas E; Cascone T; Rice DC; Sepesi B; Kalhor N; Moran C; Vaporciyan A; Heymach J; Gibbons DL; Lee JJ; Kadara H; Wistuba I; Behrens C; Solis LM
    Cancer Immunol Immunother; 2021 Jul; 70(7):1965-1976. PubMed ID: 33416944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
    Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic Profiling of Lung Adenocarcinoma in Never-Smokers.
    Devarakonda S; Li Y; Martins Rodrigues F; Sankararaman S; Kadara H; Goparaju C; Lanc I; Pepin K; Waqar SN; Morgensztern D; Ward J; Masood A; Fulton R; Fulton L; Gillette MA; Satpathy S; Carr SA; Wistuba I; Pass H; Wilson RK; Ding L; Govindan R
    J Clin Oncol; 2021 Nov; 39(33):3747-3758. PubMed ID: 34591593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
    Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
    Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Biton J; Mansuet-Lupo A; Pécuchet N; Alifano M; Ouakrim H; Arrondeau J; Boudou-Rouquette P; Goldwasser F; Leroy K; Goc J; Wislez M; Germain C; Laurent-Puig P; Dieu-Nosjean MC; Cremer I; Herbst R; Blons H; Damotte D
    Clin Cancer Res; 2018 Nov; 24(22):5710-5723. PubMed ID: 29764856
    [No Abstract]   [Full Text] [Related]  

  • 11. Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors.
    Pros E; Saigi M; Alameda D; Gomez-Mariano G; Martinez-Delgado B; Alburquerque-Bejar JJ; Carretero J; Tonda R; Esteve-Codina A; Catala I; Palmero R; Jove M; Lazaro C; Patiño-Garcia A; Gil-Bazo I; Verdura S; Teulé A; Torres-Lanzas J; Sidransky D; Reguart N; Pio R; Juan-Vidal O; Nadal E; Felip E; Montuenga LM; Sanchez-Cespedes M
    Ann Oncol; 2020 Feb; 31(2):274-282. PubMed ID: 31959344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microarray analysis of the expression profile of immune-related gene in rapid recurrence early-stage lung adenocarcinoma.
    Liu J; Yang X; Zhang L; Yang B; Rao W; Li M; Dai N; Yang Y; Qian C; Zhang L; Xiao H; Wang D
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2299-2310. PubMed ID: 32556504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing.
    Chun YJ; Choi JW; Hong MH; Jung D; Son H; Cho EK; Min YJ; Kim SW; Park K; Lee SS; Kim S; Kim HR; Cho BC;
    PLoS One; 2019; 14(11):e0224379. PubMed ID: 31765373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies.
    Dong ZY; Zhang C; Li YF; Su J; Xie Z; Liu SY; Yan LX; Chen ZH; Yang XN; Lin JT; Tu HY; Yang JJ; Zhou Q; Sun YL; Zhong WZ; Wu YL
    J Thorac Oncol; 2018 Jan; 13(1):85-96. PubMed ID: 29127022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
    Skoulidis F; Byers LA; Diao L; Papadimitrakopoulou VA; Tong P; Izzo J; Behrens C; Kadara H; Parra ER; Canales JR; Zhang J; Giri U; Gudikote J; Cortez MA; Yang C; Fan Y; Peyton M; Girard L; Coombes KR; Toniatti C; Heffernan TP; Choi M; Frampton GM; Miller V; Weinstein JN; Herbst RS; Wong KK; Zhang J; Sharma P; Mills GB; Hong WK; Minna JD; Allison JP; Futreal A; Wang J; Wistuba II; Heymach JV
    Cancer Discov; 2015 Aug; 5(8):860-77. PubMed ID: 26069186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients.
    Falk AT; Yazbeck N; Guibert N; Chamorey E; Paquet A; Ribeyre L; Bence C; Zahaf K; Leroy S; Marquette CH; Cohen C; Mograbi B; Mazières J; Hofman V; Brest P; Hofman P; Ilié M
    Lung Cancer; 2018 Jul; 121():70-75. PubMed ID: 29858030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wild-type epidermal growth-factor receptor cases.
    Mori S; Motoi N; Ninomiya H; Matsuura Y; Nakao M; Mun M; Okumura S; Nishio M; Morikawa T; Ishikawa Y
    Pathol Int; 2017 Jan; 67(1):37-44. PubMed ID: 27976463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression.
    Wang H; Gao J; Zhang R; Li M; Peng Z; Wang H
    Int Immunopharmacol; 2020 Jun; 83():106478. PubMed ID: 32278132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Predictive Value of
    Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
    Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 33.